What the data reveals about hMPV

Every year from October to April, respiratory viruses contribute to a large number of respiratory infections and hospitalisations. Respiratory tract infections (RTIs) can affect people of all ages, but young children and older adults face the greatest risk of severe disease and hospitalisation. Understanding the role of different respiratory pathogens is therefore important for informing clinical practice, surveillance, and future research.

When discussing respiratory viruses, the conversation typically focuses on RSV, influenza, and SARS-CoV-2. These pathogens are among the most intensively monitored respiratory viruses and receive substantial attention from researchers, clinicians, and public health authorities. However, other respiratory pathogens may receive less attention despite their relevance in clinical practice.

What about hMPV?

Human metapneumovirus (hMPV) is a respiratory virus that can cause symptoms such as fever, coughing, and a runny nose, while also leading to more severe respiratory disease in vulnerable populations. Like other respiratory viruses, it disproportionately affects young children, older adults, and immunocompromised individuals.

Yet compared with RSV, influenza and SARS-CoV-2, hMPV receives considerably less attention in discussions around respiratory disease burden. As testing and surveillance efforts often focus on a limited number of respiratory pathogens, evidence generation is typically stronger for these viruses. As a result, the role of hMPV in respiratory disease may be less well understood than that of other respiratory pathogens. However, hospital real-world data (RWD) offers an opportunity to further explore its impact.

While hMPV is less frequently discussed than RSV, influenza and SARS-CoV-2, published evidence suggests it can lead to hospitalization in a substantial proportion of patients with laboratory-confirmed infection. Hospital real-world data can help provide additional insight into its role among respiratory infections. Continued research and monitoring may contribute to a better understanding of its impact on patients and healthcare systems (Miao et al., 2026).

Such observations highlight the value of RWD. By linking pathogen testing results with healthcare resource utilisation (HCRU) data, researchers and clinicians can generate insights into pathogens that are less frequently studied. These insights can help identify knowledge gaps and inform future research priorities.

The RTI Observatory enables this type of research. Through longitudinal RWD, it supports research into respiratory disease burden, healthcare resource utilisation and patient outcomes across a broad range of respiratory pathogens, including hMPV.

👉 Swipe through to see what the data reveals.